Skip to main content
. 2009 Aug 24;11(5):541–547. doi: 10.1038/aja.2009.53

Figure 1.

Figure 1

Expression of TRPC6 in BPH, prostate cancer and metastatic cancer (brown denotes positive). (A): Control group of BPH ( × 400) showing no staining when the primary antibody was omitted. (B): Immunohistochemistry staining of TRPC6 in BPH (×400). Arrow indicates faint staining. (C): Control group of prostate cancer ( × 400) showing no staining when the primary antibody was omitted. (D): Immunohistochemistry staining of TRPC6 in well-differentiated prostate cancer (×400). (E): Immunohistochemistry staining of TRPC6 in moderately differentiated prostate cancer (×400). (F): Immunohistochemistry staining of TRPC6 in poorly differentiated prostate cancer ( × 400). (G): Immunohistochemistry staining of TRPC6 in peritoneal metastasis of prostate cancer ( × 100). (H): Immunohistochemistry staining of TRPC6 in bladder metastasis of prostate cancer ( × 100). (A)–(F): Scale bars = 50 μm; (G) and (H): Scale bars = 200 μm.